Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

After its blockbuster Q1 2026 earnings report that caused shares to gain 9.8%, pharmaceutical behemoth Eli Lilly and Company NYSE: LLY continues to rack up wins. These include a Food and Drug Administration (FDA) proposal that would pressure compounders, as well as strong clinical results for its oral GLP-1, Foundayo.